The FTC’s Health Care Work
When health care markets are competitive, consumers benefit from lower costs, better care and more innovation. The Federal Trade Commission enforces the antitrust laws in health care markets to prevent anticompetitive conduct that would deprive consumers of the benefits of competition. The agency also gives guidance to participants in the health care market - including physicians and other health professionals, hospitals and other institutional providers, pharmaceutical companies and other sellers of health care products, and insurers - to help them comply with U.S. antitrust laws. The FTC maintains its expertise in health care markets by doing research and issuing reports on competition issues, which in the past have included empirical studies of generic drug entry, contact lens sales, and mail order pharmacies, and economic analyses of the effects of mergers involving non-profit hospitals.
- Caremark Rx, Zinc Health Services, et al., In the Matter of (Insulin) ( )
- GTCR BC Holdings, LLC and Surmodics, Inc., In the Matter of ( )
- Mercury Marketing LLC, FTC v. ( )
- Welsh, Carson, Anderson & Stowe, In the Matter of ( )
- B4B Corp. ( )
- SuperGoodDeals.com, Inc. ( )
- LCA-Vision Inc. d/b/a LasikPlus ( )
- Illumina, Inc., and GRAIL, Inc., In the Matter of ( )
- Novant Health, Inc. and Community Health Systems, Inc., In the Matter of ( )
- Legion Media LLC, et al., FTC v. ( )
- Cerebral, Inc. and Kyle Robertson, U.S. v. ( )
- Simple Health Plans LLC ( )
- Zaappaaz LLC ( )
- Benefytt Technologies, et al., FTC v. ( )
- The Bountiful Company ( )
- IQVIA Holdings/Propel Media, In the Matter of ( )
- Vyera Pharmaceuticals, LLC ( )
- John Muir Health/Tenet Healthcare Co., In the Matter of ( )
- Sanofi/Maze Therapeutics, Inc., In the Matter of ( )
- Amgen, Inc. and Horizon Therapeutics plc, In the Matter of ( )
- FTC and DOJ Host Listening Session on Lowering Americans’ Drug Prices Through Competition ( )
- FTC and DOJ to Host Listening Sessions on Lowering Americans’ Drug Prices Through Competition ( )
- FTC Announces Workshop on Exploring Unfair or Deceptive Trade Practices in “Gender-Affirming Care” for Minors ( )
- FTC Sends Warning Letters to Prescribers Regarding Possible Violations of the Contact Lens Rule ( )
- FTC Renews Challenge of More Than 200 Improper Patent Listings ( )
- FTC Approves Final Order with Welsh Carson ( )
- Illinois and Minnesota Join FTC Lawsuit Challenging Medical Device Coatings Deal ( )
- FTC Staff Reaffirm Opposition to Proposed Indiana Hospital Merger ( )
- FTC Challenges Medical Device Coatings Deal ( )
- FTC Secures Settlement with Private Equity Firm in Antitrust Roll-Up Scheme Case ( )
- FTC Releases Second Interim Staff Report on Prescription Drug Middlemen ( )
- FTC Announces Tentative Agenda for January 14 Open Commission Meeting ( )
- FTC Announces Refund Claims Process for Consumers Who Bought Deceptively Marketed Golden Sunrise Nutraceutical Products ( )
- FTC Statement on Appellate Court Decision Ordering Delisting of Teva Inhaler Patents ( )
- FTC Staff Sends Warning Letters to Healthcare Plan Marketers and Lead Generators ( )
- FTC Approves Modification of Cooperativa De Farmacias Puertorriqueñas Final Commission Order ( )
- Statement Regarding Union Health’s COPA Application Withdrawal ( )
- FTC Sends More Than $1.1 Million in Refunds to Consumers Deceived by Bait-and-Switch Ads for LASIK Vision Correction Procedures ( )
- FTC Sues Prescription Drug Middlemen for Artificially Inflating Insulin Drug Prices ( )
- FTC Staff Opposes Proposed Indiana Hospital Merger ( )
- Enforcing the Opioid Addiction Recovery Fraud Prevention Act: The FTC’s settlement with Evoke Wellness and what it means for businesses( )
- Focus on the Eyeglass and Contact Lens Rules: The FTC’s message to prescribers( )
- Physician Group and Healthcare Facility Merger Study( )
- A prescription for complying with the Eyeglass Rule( )
- MMA Reports: No tricks or treats—just facts( )
- FTC updates the Contact Lens Rule: What it means for prescribers and sellers( )
- Then, now, and down the road: Trends in pharmaceutical patent settlements after FTC v. Actavis( )
- Control no longer controlling for HSR reporting of not-for-profit combinations( )
- Insights into contact lenses: FTC workshop will focus on the Contact Lens Rule( )
- Quo Vadis Post-Actavis?( )
- Antitrust Violation vs. Injury-in-Fact: A distinction that makes a difference( )
- Is FTC v. Actavis Causing Pharma Companies to Change Their Behavior?( )
- Monitors: Expert eyes and ears in Commission orders( )
- From the antitrust mailbag: What can the FTC do about prescription drug price spikes?( )
- Power shopping for an alternative buyer( )
- Listening Sessions on Lowering Americans’ Drug Prices Through CompetitionAugust 4, 2025
- Listening Sessions on Lowering Americans’ Drug Prices Through CompetitionJuly 24, 2025
- The Dangers of “Gender-Affirming Care” for MinorsJuly 9, 2025
- Listening Sessions on Lowering Americans’ Drug Prices Through CompetitionJune 30, 2025
- Scheduling Conference before Administrative Law Judge Jay L. Himes, In the Matter of GTCR BC Holdings, LLC and Surmodics, Inc., Docket 9440 March 28, 2025
- Private Capital, Public Impact: An FTC Workshop on Private Equity in Health CareMarch 5, 2024
- Prehearing scheduling conference in the matter of Novant Health, Inc. & Community Health Systems, Inc. - February 20, 2024February 20, 2024
- Open Commission Meeting - July 20, 2023July 20, 2023
- Open Commission Meeting - February 17, 2022February 17, 2022
- PrivacyCon 2021July 27, 2021
- PrivacyCon 2020July 21, 2020
- FDA / FTC Workshop on a Competitive Marketplace for BiosimilarsMarch 9, 2020
- A Health Check on COPAs: Assessing the Impact of Certificates of Public Advantage in Healthcare MarketsJune 18, 2019
- Understanding Competition in Prescription Drug Markets: Entry and Supply Chain DynamicsNovember 8, 2017
- Now Hear This: Competition, Innovation, and Consumer Protection Issues in Hearing Health CareApril 18, 2017
- Examining Health Care CompetitionFebruary 24, 2015
- Conditional Pricing Practices: Economic Analysis and Legal Policy ImplicationsJune 23, 2014
- Examining Health Care CompetitionMarch 20, 2014
- Follow-On Biologics Workshop: Impact of Recent Legislative and Regulatory Naming Proposals on CompetitionFebruary 4, 2014
- Consumer Protection and the Healthcare MarketplaceSeptember 19, 2013
- Statement of Chair Lina M. Khan In the Matter of Caremark/ESI/Optum ( )
- Statement of Chair Lina M. Khan Joined by Commissioner Rebecca Kelly Slaughter and Commissioner Alvaro M. Bedoya In the Matter of Welsh, Carson, Anderson & Stowe ( )
- Concurring Statement of Commissioner Andrew N. Ferguson Joined by Commissioner Melissa Holyoak In the Matter of US Anesthesia Partners/Guardian Anesthesia ( )
- Concurring Statement of Commissioner Andrew N. Ferguson Joined by Commissioner Melissa Holyoak Regarding the Second Pharmacy Benefit Managers Interim Staff Report ( )
- Statement of Commissioner Melissa Holyoak In the Matter of Cooperativa De Farmacias Puertorriqueña ( )
- Statement of Chair Lina M. Khan In the Matter of Cooperativa de Farmacias Puertoriqueñas ( )
- Statement of FTC Bureau of Competition Deputy Director Rahul Rao on Lawsuit Against PBMs and the Role of Drug Manufacturers in Distorting Competition in the U.S Drug Distribution System ( )
- FDA Draft Guidance Biosimilar Drugs Comment Letter ( )
- Statement of Commissioner Rebecca Kelly Slaughter Regarding FTC Staff Interim Report: Pharmacy Benefit Managers ( )
- Concurring Statement of Commissioner Andrew N. Ferguson Regarding the Pharmacy Benefit Managers Interim Staff Report ( )
- Statement of Chair Lina M. Khan Joined by Commissioners Alvaro M. Bedoya & Rebecca Kelly Slaughter Regarding the Pharmacy Benefit Managers Interim Staff Report ( )
- Dissenting Statement of Commissioner Melissa Holyoak In the Matter of the Pharmacy Benefit Managers Report ( )
- Statement of Commissioner Rebecca Kelly Slaughter Regarding the Eyeglass Rule ( )
- Chair Khan Opening Statement at House Committee on Appropriations , Subcommittee on Financial Services and General Government ( )
- Remarks by Chair Lina M. Khan As Prepared for Delivery at White House Event on Lowering Healthcare Costs ( )
- Remarks by Chair Lina M. Khan As Prepared for Delivery at the Private Capital, Public Impact Workshop on Private Equity in Healthcare ( )
- Remarks by Chair Lina M. Khan As Prepared for Delivery for White House Roundtable on PBMs ( )
- Remarks by Chair Lina M. Khan at American Medical Association National Advocacy Conference ( )
- Comment of the United States Federal Trade Commission - Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights ( )
- Statement of Chair Lina M. Khan Joined by Commissioner Rebecca Kelly Slaughter In the Matter of Sanofi/Maze Therapeutics ( )
- Staff Opinion Letter Concerning Discounted Pharmaceuticals and Medical Devices Under the Non-Profit Institutions Act ( )
- Letter From Markus H. Meier, Assistant Director, Bureau of Competition, Concerning Crouse Health Hospital's Proposal To Sell Discounted Pharmaceutical Products to the Employees, Retirees, and Their Dependents of Its Affiliate, Dated October 20, 2017 ( )
- American Medical Association ( )
- Advisory opinion on the permissibility under the antitrust laws of a system of professional society peer review of physicians' fees ( )
- Advisory opinion on the application of the Non-Profit Institutions Act, 15 U.S.C. § 13c, to sales of pharmaceuticals by non-profit hospitals to related non-profit long-term care facilities ( )
- Presentation Health System ( )
- Advisory opinion concerning the legality of the American Society of Internal Medicine's proposal to develop and disseminate relative value guides ( )
- American Society of Internal Medicine ( )
- Specialty Generic Drugs: A Growing Profit Center for Vertically Integrated Pharmacy Benefit Managers ( )
- Summary Report on the FDA/FTC Workshop on a Competitive Marketplace for Biosimilars ( )
- Federal Trade Commission Report on Pharmaceutical Product Hopping ( )
- Order to File Special Report Regarding Physician Group and Healthcare Facility Mergers ( )
- Order to File Special Report to Collect Information Regarding Certificates of Public Advantage (COPA) ( )
- Prices for Medical Services Vary Within Hospitals, But Vary More Across Them ( )
- Simulating Hospital Merger Simulations ( )
- The effects of physician and hospital integration on Medicare beneficiaries’ health outcomes ( )
- Why is Distance Important for Hospital Choice? Separating Home Bias from Transport Costs ( )
- Price Effects of a Merger: Evidence from a Physicians’ Market ( )
- Federal Trade Commission Staff Report on the Homeopathic Medicine & Advertising Workshop ( )
- Direct-to-Consumer Advertising and Online Search ( )
- Competition in the Pet Medications Industry: Prescription Portability and Distribution Practices ( )
- Agreements Filled With the Federal Trade Commission Under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003: Overview of Agreements Filed In Fiscal Year 2013: A Report By the Bureau of Competition ( )
- Banning Foreign Pharmacies from Sponsored Search: The Online Consumer Response ( )
- Self-Regulation in the Alcohol Industry: Report of the Federal Trade Commission ( )
- Policy Perspectives: Competition and the Regulation of Advanced Practice Nurses ( )
- Economics at the FTC: Physician Acquisitions, Standard Essential Patents, and Accuracy of Credit Reporting ( )
- Agreements Filed With the Federal Trade Commission Under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003: Overview of Agreements Filed in Fiscal Year 2012: A Report by the Bureau of Competition ( )
- Agreements Filed With the Federal Trade Commission Under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003: Overview of Agreements Filed in Fiscal Year 2011: A Report by the Bureau of Competition ( )
- Staff Submission to Indiana Health Department Regarding the COPA Application of Union Health and Terre Haute Regional Hospital ( )
- FTC Staff Comment to Department of Labor on Proposed Amendments to Regulations Implementing the Mental Health Parity and Addiction Equity Act ( )
- FTC Staff Comment Concerning North Carolina Senate Bill 743 ( )
- FTC Staff Submission to NYS Health Department Regarding the COPA Application of SUNY Upstate Medical University and Crouse Health System ( )
- FTC Staff Comment to Department of Veterans Affairs Concerning Authority of VA Professionals to Practice Healthcare ( )
- FTC Staff Comment to Texas Health and Human Services Commission Regarding Certificate of Public Advantage Applications ( )
- FTC Staff Comment to Attorney General of Texas Concerning Certified Registered Nurse Anesthetists (CRNA) Regulations ( )
- FTC Staff Letter to the Centers for Medicare and Medicaid Services Regarding the Interim Final Rule with Policy and Regulatory Revisions in Response to the COVID-19 Public Health Emergency ( )
- FTC Staff Letter to Department of Health and Human Services Concerning the 21st Century Cures Act: Interoperability, Information Blocking and the ONC Health IT Certification Program Rule ( )
- FTC Staff Comment to the Kansas House of Representatives Concerning Kansas House Bill 2412 ( )
- FTC Staff Comment to the Ohio House of Representatives Concerning Ohio House Bill 177 ( )
- FTC Staff Comment to the North Carolina State Board of Dental Examiners Regarding Proposed Rule Changes to 21 N.C. Admin. Code 16W ( )
- Comment of the Staff of the Federal Trade Commission to Massachusetts Rep. Paul J. Donato regarding HB1869 and SB1329 ( )
- FTC Staff Comment Before the Department of Health and Human Services Regarding the 21st Century Cures Act: Interoperability, Information Blocking, and the ONC Health IT Certification Program ( )
- FTC Staff Comment to the FDA Department of Health and Human Services on Its Updated Guidance for Industry on the “Nonproprietary Naming of Biological Products” ( )
- Statement of the Federal Trade Commission to the Alaska Senate Committee on Health & Social Services on Certificate of Need Laws and SB 1 ( )
- Federal Trade Commission Comment On the Food and Drug Administration’s Revised Draft Guidance For Industry, Entitled “Citizen Petitions and Petitions For Stay of Action Subject To Section 505(q) of the Federal Food, Drug, and Cosmetic Act.” ( )
- FTC Staff Comment on New York's proposal to allow licensure by endorsement of Canadian dental licenses ( )
- FTC Staff Comment to Washington State Rep. Paul Graves, regarding S.S.B. 5411/H.B. 1473 ( )
- Federal Trade Commission Staff Comment Before the Pennsylvania State House of Representatives Regarding the Likely Competitive Impact of House Bill 100 On Advanced Practice Registered Nurse-Certified Nurse Practitioners ( )
- Mylan Pharmaceuticals, et al. v. Sanofi-Aventis, et al. ( )
- Sage Chemical, Inc. et al. v. Supernus Pharmaceuticals, Inc. et al. ( )
- Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC ( )
- SmileDirectClub, LLC v. Battle, et al. ( )
- D. Blaine Leeds and SmileDirectClub, LLC v. Jackson, et al. ( )
- Takeda Pharmaceutical Company Limited, et al. v. Zydus Pharmaceuticals (USA) Inc., et al. ( )
- Amphastar Pharmaceuticals, Inc., et al. v. Momenta Pharmaceuticals, Inc., et al. ( )
- Mylan Pharmaceuticals Inc. v. Warner Chilcott PLC ( )
- Teladoc, Incorporated, et al. v. Texas Medical Board et al. ( )
- In re Wellbutrin Antitrust Litigation ( )
- Mylan Pharmaceuticals, Inc. v. Warner Chilcott plc, et al. ( )
- Wellbutrin XL Antitrust Litigation, In re ( )
- In re K-Dur Antitrust Litigation ( )
- Arkansas Carpenters Health and Welfare Fund, et. al v. Bayer AG, et. al (In re Ciprofloxacin Hydrochloride Antitrust Litigation) ( )
- In re Ciprofloxacin Hydrochloride Antitrust Litigation ( )
- In re DDAVP Direct Purchaser Antitrust Litigation ( )
- In re Tamoxifen Citrate Antitrust Litigation ( )
- Teva Pharmaceuticals USA, Inc. v. Pfizer, Inc. ( )
- Andrx Pharmaceuticals, Inc. v. Kroger Co ( )
- Jackson, Tennessee Hospital Co. v. West Tennessee Healthcare, Inc ( )
- Stopping COVID-19 Fraud and Price Gouging ( )
- Prepared Statement of the Federal Trade Commission: Curbing COVID Cons: Warning Consumers about Pandemic Frauds, Scams, and Swindles ( )
- Prepared Statement of the Federal Trade Commission On “Oversight of the Enforcement of the Antitrust Laws” ( )
- Prepared Statement of the Federal Trade Commission On "Oversight of the Enforcement of the Antitrust Laws" ( )
- Prepared Statement of the Federal Trade Commission On Pay-For-Delay Deals: Limiting Competition and Costing Consumers ( )
- Prepared Statement of the Federal Trade Commission, "Oversight of the Enforcement of the Antitrust Laws" ( )
- Prepared Statement of the Federal Trade Commission on Antitrust Enforcement in the Health Care Industry ( )
- Prepared Statement of the Federal Trade Commission: Oversight of the Federal Trade Commission Bureau of Competition and the Department of Justice Antitrust Division ( )
- Prepared Statement of the Federal Trade Commission Concerning "The Community Pharmacy Fairness Act of 2007" ( )
- Prepared Statement of the Federal Trade Commission On Protecting Consumer Access To Generic Drugs: The Benefits Of A Leglislative Solution To Anticompetitive Patent Settlements In The Pharmaceutical Industry ( )
- Prepared Statement of the Federal Trade Commission On Internet, and Intellectual Property ( )
- Prepared Statement of the Federal Trade Commission On Health Care Competition ( )
- Prepared Statement of the Federal Trade Commission On Health Care Competition ( )
- Prepared Statement of the Federal Trade Commission On Generic Drug Entry ( )
- Prepared Statement of the Federal Trade Commission On Subcommittee on Federal Financial Management, Government Information, and International Security of the Committee on Homeland Security and Governmental Affairs, United States Senate ( )
- Prepared Statement of the Federal Trade Commission On Contact Lens Legislation ( )
- Prepared Statement of the Federal Trade Commission On Greater Access to Affordable Pharmaceuticals Act ( )
- Prepared Statement of Chairman Timothy J. Muris On Competition In the Pharmaceutical Industry ( )
- Prepared Statement of the Federal Trade Commission On Competition in the U.S. Pharmaceutical Industry ( )
- Prepared Statement of the Federal Trade Commission On Pharmaceutical Industry ( )
